Literature DB >> 31031981

Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.

Saudade André1, Teresa Pereira1, Fernanda Silva2, Patrícia Machado3, Fátima Vaz3, Mariana Aparício4, Giovani L Silva4,5, António E Pinto1.   

Abstract

Male breast cancer (BC) represents an individual subtype of BC, with therapeutic procedures based on female BC therapy results. The present study evaluated the parameters currently used for the characterization and therapy of male BC, and their association with disease-free (DFS) and overall survival (OS), aiming to obtain a comprehensive basis to improve the personalized care of male BC. A total of 196 patients from March 1970 to March 2018 (mean follow-up, 84.9 months) were profiled, using clinicopathological review, molecular assessment [BRCA1/2, DNA repair associated (BRCA1/2) status, immunohistochemistry, fluorescence in situ hybridization and DNA flow cytometry] and Cox regression statistical analysis. The median age of patients was 66.5 years. At presentation, 39.2% of patients with invasive carcinomas were in anatomic stage (AS) I. Patients exhibited primarily invasive carcinomas of no special type, histological grade 2, estrogen receptor α-(ERα) and progesterone receptor (PR)-positive, receptor tyrosine kinase erbB-2-negative, high Ki-67, Luminal B-like and aneuploid tumors. A total of 13 of the 44 (29.5%) BRCA-evaluated patients exhibited BRCA2 mutations, significantly associated with family history (FH), bilaterality, high Ki-67 expression, absence of PR and Luminal B-like tumors. Bilaterality was associated with the occurrence of non-breast primary neoplasms (NBPN). The 5 and 10-year DFS rates, excluding patients with distant metastasis, NBPN and in situ carcinomas (n=145) were 65.9 and 58.2%, respectively, and the 5 and 10-year OS rates were 77.5 and 59.2%, respectively. In the univariate analysis, Luminal B-like subtype, BRCA2 mutations, high Ki-67 expression, and AS II and III were significantly associated with shorter DFS and OS. In addition, age >70 years was associated with low OS. In the multivariate analysis, FH, AS II and III, and Luminal B-like subtypes were associated with poorer OS. In conclusion, the data from the present study emphasize the high incidence of BRCA2 mutation in male BC, and its association with FH, bilaterality, high Ki-67 expression, negative PR expression and Luminal B-like subtypes, and with shorter DFS and OS in univariate analysis.

Entities:  

Keywords:  clinicopathological characteristics; male breast cancer; molecular features; survival

Year:  2019        PMID: 31031981      PMCID: PMC6482395          DOI: 10.3892/mco.2019.1841

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  6 in total

1.  Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.

Authors:  Ksenija Strojnik; Mateja Krajc; Vita Setrajcic Dragos; Vida Stegel; Srdjan Novakovic; Ana Blatnik
Journal:  Breast Cancer Res Treat       Date:  2021-04-23       Impact factor: 4.872

2.  Male Breast Cancer-Immunohistochemical Patterns and Clinical Relevance of FASN, ATF3, and Collagen IV.

Authors:  Saudade André; António E Pinto; Giovani L Silva; Fernanda Silva; Jacinta Serpa; Ana Félix
Journal:  Breast Cancer (Auckl)       Date:  2021-04-08

Review 3.  Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.

Authors:  Dylan P McClurg; Gordan Urquhart; Trevor McGoldrick; Subarnarekha Chatterji; Zosia Miedzybrodzka; Valerie Speirs; Beatrix Elsberger
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 4.  Epstein-Barr Virus Association with Breast Cancer: Evidence and Perspectives.

Authors:  Claudia Arias-Calvachi; Rancés Blanco; Gloria M Calaf; Francisco Aguayo
Journal:  Biology (Basel)       Date:  2022-05-24

5.  Male and female breast cancer: the two faces of the same genetic susceptibility coin.

Authors:  Susana Nunes Silva; Bruno Costa Gomes; Saudade André; Ana Félix; António Sebastião Rodrigues; José Rueff
Journal:  Breast Cancer Res Treat       Date:  2021-05-03       Impact factor: 4.872

6.  Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer.

Authors:  Saudade André; Sandra P Nunes; Fernanda Silva; Rui Henrique; Ana Félix; Carmen Jerónimo
Journal:  Int J Mol Sci       Date:  2020-04-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.